Search results
Results from the WOW.Com Content Network
It is a positive regulator for gene transcription. It has been shown that associates with Host cell factor C1, CREB binding protein, WDR5, CTBP, MEN1, etc. The rearrangement of MLL are related with different kinds of aggressive acute leukemias. Most of biphenotypic leukemia in children is due to the rearrangement of MLL [7] Protein MLL PDB 2j2s
Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white blood cells) are found in the blood and bone marrow. It is the most common type of acute lymphoblastic leukemia (ALL). It is sometimes additionally classified as a lymphoma, as designated leukemia/lymphoma. ALL is the ...
Central nervous system (CNS) symptoms such as cranial neuropathies due to meningeal infiltration are identified in less than 10% of adults and less than 5% of children, particularly mature B-cell ALL (Burkitt leukemia) at presentation. [20] The signs and symptoms of acute lymphoblastic leukemia are variable and include: [21]
Chronic lymphocytic leukemia; Other names: B-cell chronic lymphocytic leukemia (B-CLL) [1] Peripheral blood smear showing CLL cells: Specialty: Hematology and oncology: Symptoms: Early: None [2] Later: Non-painful lymph nodes swelling, feeling tired, fever, weight loss, night sweats [2] Usual onset: Older than 50 [3] Risk factors
A B-cell leukemia is any of several types of lymphoid leukemia which affect B cells. [1] Types include (with ICD-O code): [citation needed] 9823/3 – B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma; 9826/3 – Acute lymphoblastic leukemia, mature B-cell type; 9833/3 – B-cell prolymphocytic leukemia
Monoclonal B-cell lymphocytosis; Other names: monoclonal lymphocytosis of undetermined significance: Specialty: Hematology, oncology: Symptoms: None: Complications: May progress to chronic lymphocytic leukemia or certain lymphoma types; increased risk of developing non-hematologic cancers, serious infections, and kidney disease
Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies.It is the most common form of non-Hodgkin lymphoma among adults, [1] with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK.
Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. [1] It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), which plays a role in the pathogenesis of these leukemias. [2] It is ...